Deutsche Bank AG Reaffirms “Buy” Rating for Qiagen N.V. (QGEN)
A number of other brokerages have also commented on QGEN. Zacks Investment Research raised shares of Qiagen N.V. from a hold rating to a buy rating and set a $39.00 price objective for the company in a research report on Tuesday, October 10th. Bank of America Corporation reaffirmed a neutral rating and set a $36.00 price objective (up previously from $33.00) on shares of Qiagen N.V. in a research report on Friday, July 21st. Commerzbank Ag reissued a buy rating on shares of Qiagen N.V. in a research note on Friday, July 28th. Barclays PLC reissued an overweight rating and issued a $37.00 target price (up previously from $33.00) on shares of Qiagen N.V. in a research note on Monday, July 17th. Finally, BidaskClub raised shares of Qiagen N.V. from a hold rating to a buy rating in a research note on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company. The company has an average rating of Hold and a consensus target price of $34.06.
Qiagen N.V. (NASDAQ QGEN) traded down $0.07 during mid-day trading on Wednesday, hitting $31.54. 1,130,400 shares of the company traded hands, compared to its average volume of 962,382. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.34 and a current ratio of 5.33. Qiagen N.V. has a 1-year low of $27.51 and a 1-year high of $36.34. The firm has a market cap of $7,196.34, a price-to-earnings ratio of 25.70, a PEG ratio of 1.93 and a beta of 1.13.
Qiagen N.V. (NASDAQ:QGEN) last released its quarterly earnings data on Monday, November 6th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.32. The business had revenue of $364.00 million during the quarter, compared to analyst estimates of $363.42 million. Qiagen N.V. had a net margin of 6.40% and a return on equity of 11.36%. Qiagen N.V.’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.29 EPS. sell-side analysts anticipate that Qiagen N.V. will post 1.25 earnings per share for the current fiscal year.
WARNING: This article was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/deutsche-bank-ag-reaffirms-buy-rating-for-qiagen-n-v-qgen/1696010.html.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its stake in shares of Qiagen N.V. by 12.9% during the third quarter. Wells Fargo & Company MN now owns 86,594 shares of the company’s stock valued at $2,727,000 after purchasing an additional 9,864 shares during the last quarter. Trexquant Investment LP bought a new stake in shares of Qiagen N.V. during the third quarter valued at approximately $234,000. Legal & General Group Plc grew its stake in shares of Qiagen N.V. by 0.8% during the third quarter. Legal & General Group Plc now owns 1,909,956 shares of the company’s stock valued at $52,573,000 after purchasing an additional 15,660 shares during the last quarter. FNY Partners Fund LP grew its stake in shares of Qiagen N.V. by 272.4% during the third quarter. FNY Partners Fund LP now owns 43,403 shares of the company’s stock valued at $1,367,000 after purchasing an additional 31,749 shares during the last quarter. Finally, Van ECK Associates Corp grew its stake in shares of Qiagen N.V. by 11.8% during the third quarter. Van ECK Associates Corp now owns 687,826 shares of the company’s stock valued at $21,667,000 after purchasing an additional 72,605 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.